In this piece, we will look at the stocks Jim Cramer recently discussed.

While S&P 500 is at its all-time high, Danaher is still ~34% below its peak from late 2021. The company was beleaguered with ...

(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending ...

Danaher Corp soared in the stock market after announcing better-than-expected second-quarter results. The company reported ...

This was the stock's second consecutive day of gains.

Danaher reported generating $1.1 billion in free cash flow during the quarter, with adjusted diluted net earnings per share increasing by approximately 5% year-over-year. This financial strength ...

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...

Montag A & Associates Inc. took a step back from Danaher, slashing their stake by a hefty 28.6%. The firm sold 8,037 shares, ...

Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Danaher (NYSE:DHR) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free ...